> NuPathe, the maker of the Zecuity transdermal patch for migraine treatment, decided not to accept Endo Health Solutions' ($ENDP) offer of about $105 million and opted instead for Teva Pharmaceutical Industries' ($TEVA) offer of about $114 milliion. More
> Alnylam ($ALNY) entered the clinic with its RNAi candidate ALN-AT3. The Phase I trial will focus on the treatment of hemophilia and rare bleeding disorders. Release
> New Jersey-based Alitair Pharmaceuticals won a U.S. patent for its ion exchange resin drug delivery technology. Release